Clinical Utility of Epidermal Growth Factor Receptor Expression for Selecting Patients with Advanced Non-small Cell Lung Cancer for Treatment with Erlotinib

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

2005 • 5,383 citations

EGFR and cancer prognosis

2001 • 2,068 citations

Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome

2005 • 1,834 citations

TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer

2005 • 1,517 citations

Epidermal Growth Factor Receptor in Non–Small-Cell Lung Carcinomas: Correlation Between Gene Copy Number and Protein Expression and Impact on Prognosis

2003 • 1,445 citations

Dangers of Using "Optimal" Cutpoints in the Evaluation of Prognostic Factors

1994 • 1,107 citations

Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry

2005 • 1,081 citations

Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer

2004 • 1,080 citations

Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib

2005 • 782 citations

Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced Non-Small-Cell Lung Cancer

2004 • 371 citations

Immunohistochemical Detection of EGFR in Paraffin-embedded Tumor Tissues

2004 • 320 citations

Immunocytochemical markers in stage I lung cancer: relevance to prognosis.

1997 • 313 citations

Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC)

2004 • 301 citations

The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis

2002 • 267 citations

Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression.

2000 • 261 citations

Epidermal Growth Factor Receptor (EGFR) Status in Primary Colorectal Tumors Does Not Correlate With EGFR Expression in Related Metastatic Sites: Implications for Treatment With EGFR-Targeted Monoclonal Antibodies

2004 • 259 citations

The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival

1993 • 224 citations

Gefitinib in Pretreated Non–Small-Cell Lung Cancer (NSCLC): Analysis of Efficacy and Correlation With HER2 and Epidermal Growth Factor Receptor Expression in Locally Advanced or Metastatic NSCLC

2003 • 213 citations

Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (‘Iressa’, ZD1839) in non-small-cell lung cancer

2004 • 203 citations

Assessing the clinical impact of prognostic factors: When is "statistically significant" clinically useful?

1998 • 191 citations

Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa®, ZD1839) in chemotherapy‐resistant non‐small cell lung cancer

2004 • 156 citations

Why do so many prognostic factors fail to pan out?

1992 • 135 citations

Assessing epidermal growth factor receptor expression in tumours: What is the value of current test methods?

2005 • 107 citations

O-242 Gefitinib (‘Iressa’, ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer in IDEAL 1 and 2: tumor response is not clinically relevantly predictable from tumor EGFR membrane staining alone

2003 • 96 citations

Do we really need prognostic factors for breast cancer?

1994 • 84 citations

Expression of epidermal growth factor receptor (EGF-R) in non-small cell lung cancer. Use of archival tissue and correlation of EGF-R with histology, tumour size, node status and survival

1989 • 80 citations

Co-expression of epidermal growth factor receptor and transforming growth factor-α is independent of ras mutations in lung adenocarcinoma

2000 • 68 citations

Interpreting and Integrating Risk Factors for Patients With Primary Breast Cancer

2001 • 31 citations

Extensive experience of disease control with gefitinib and the role of prognostic markers

2003 • 27 citations

Is there a relationship between c-erbB-1 and c-erbB-2 amplification and protein overexpression in NSCLC?

2004 • 22 citations

Association between activation of ErbB pathway genes and survival following gefitinib treatment in advanced BAC (SWOG 0126)

2004 • 21 citations

Prognostic role of epidermal growth factor receptor in stage III nonsmall cell lung cancer

2005 • 18 citations

Molecular characteristics of non-small cell lung cancer (NSCLC) patients sensitive to gefitinib

2004 • 17 citations

Prognostic value of soft tissue metastasis (STM) in stage D2 and stage D3 prostate Cancer (PC)

2005 • 3 citations